Search research articles
Contact Us
Filters
Showing results (111-120 of 114) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 114 results.
Infection Control and Hospital Epidemiology
|
April 27, 2018
Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants
Bradley C Johnston, Lyubov Lytvyn, Calvin Ka-Fung Lo, et al.
The Lancet. Gastroenterology & Hepatology
|
March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A Kennedy, Graham A Heap, Harry D Green, et al.
Gut
|
March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Nicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.
Alimentary Pharmacology & Therapeutics
|
August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
Neil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 114) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 114 results.
Infection Control and Hospital Epidemiology
|
April 27, 2018
Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants
Bradley C Johnston, Lyubov Lytvyn, Calvin Ka-Fung Lo, et al.
The Lancet. Gastroenterology & Hepatology
|
March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A Kennedy, Graham A Heap, Harry D Green, et al.
Gut
|
March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Nicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.
Alimentary Pharmacology & Therapeutics
|
August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
Neil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Page
of 12